Stoke Therapeutics (STOK) Cash & Equivalents (2018 - 2026)

Stoke Therapeutics' Cash & Equivalents history runs 9 years deep, the most recent figure standing at $155.7 million for Q1 2026.

• In Q1 2026, Cash & Equivalents fell 43.36% year-over-year to $155.7 million; the TTM figure through Mar 2026 stood at $155.7 million (down 43.36% YoY), while the FY2025 annual figure was $84.2 million, down 34.19% from the prior year.
• Cash & Equivalents was $155.7 million for Q1 2026 at Stoke Therapeutics, up from $84.2 million in the prior quarter.
• In the past five years, Cash & Equivalents ranged from a high of $274.8 million in Q1 2025 to a low of $67.8 million in Q2 2022.
• Historically, Cash & Equivalents has averaged $146.6 million across 5 years, with a median of $150.0 million in 2024.
• The sharpest annual moves came in 2022 and 2023: Cash & Equivalents slumped 68.56% in 2022, then jumped 183.47% in 2023.
• A 5-year view of Cash & Equivalents shows it stood at $113.6 million in 2022, then soared by 68.59% to $191.4 million in 2023, then plunged by 33.15% to $128.0 million in 2024, then sank by 34.19% to $84.2 million in 2025, then surged by 84.82% to $155.7 million in 2026.
• The last three Cash & Equivalents figures came in at $155.7 million (Q1 2026), $84.2 million (Q4 2025), and $83.4 million (Q3 2025), per Business Quant data.